The decline in Ventyx Biosciences' stock price is likely due to investor reactions to the clinical data and pipeline updates. Negative or underwhelming clinical data can often lead to decreased investor confidence and a drop in stock price. The direct mention of the company and its NLRP3 inhibitor portfolio suggests a high relevance and importance of this news to Ventyx Biosciences' investors.